title: Prognostic impact of CD109 expression in myxofibrosarcoma.
abstract: BACKGROUND
  CD109, a TGF-β co-receptor, is reported to be preferentially expressed during the early stages of tumorigenesis in several carcinoma types. Myxofibrosarcoma is one of the most common soft-tissue sarcomas found in elderly patients. This study aimed to elucidate the impact of CD109 expression in myxofibrosarcoma on prognosis and recurrence.
  
  
  METHODS
  Immunohistochemical staining for CD109 was performed on archival specimens from 37 patients. The Fisher exact test was used to evaluate association between CD109 expression and other clinicopathological features. Survival analysis was performed using Kaplan-Meier curves, and the prognostic significance was evaluated using the log-rank test. Multivariate analysis of factors was performed using Cox regression analysis.
  
  
  RESULTS
  CD109 overexpression was significantly associated with surgical stage and distant metastasis (P = 0.00499, and 0.011, respectively). The frequency of CD109 overexpression was approximately 10% and CD109 overexpression was significantly associated with decreased overall survival (P = 0.004). Five-year overall survival rates 77% and 0% for CD109-negative and CD109-positive patients, respectively. In multivariate analysis, CD109 overexpression was the only independent risk factor for poor outcome (P = 0.02; hazard ratio, 10.64; 95% confidence interval, 1.47-76.91).
  
  
  CONCLUSIONS
  Immunohistochemical CD109 expression in myxofibrosarcoma was associated with poor prognosis.
authors.affiliation: Department of Orthopedic Surgery, Sapporo Medical University School of Medicine, Sapporo, Hokkaido, Japan.
authors.forename: Makoto
authors.initials: M
authors.lastname: Emori
authors.affiliation: Department of Pathology, Sapporo Medical University School of Medicine, Sapporo, Hokkaido, Japan.
authors.forename: Tomohide
authors.initials: T
authors.lastname: Tsukahara
authors.affiliation: Department of Orthopedic Surgery, Sapporo Medical University School of Medicine, Sapporo, Hokkaido, Japan.
authors.forename: Kenji
authors.initials: K
authors.lastname: Murata
authors.affiliation: Department of Diagnostic Pathology, Sapporo Medical University School of Medicine, Sapporo, Hokkaido, Japan.
authors.forename: Shintaro
authors.initials: S
authors.lastname: Sugita
authors.affiliation: Department of Public Health, Sapporo Medical University School of Medicine, Sapporo, Hokkaido, Japan.
authors.forename: Tomoko
authors.initials: T
authors.lastname: Sonoda
authors.affiliation: Department of Orthopedic Surgery, Sapporo Medical University School of Medicine, Sapporo, Hokkaido, Japan.
authors.forename: Mitsunori
authors.initials: M
authors.lastname: Kaya
authors.affiliation: Department of Orthopedic Surgery, Hokkaido Cancer Center, Sapporo, Hokkaido, Japan.
authors.forename: Tamotsu
authors.initials: T
authors.lastname: Soma
authors.affiliation: Department of Orthopedic Surgery, Sapporo Medical University School of Medicine, Sapporo, Hokkaido, Japan.
authors.forename: Mikito
authors.initials: M
authors.lastname: Sasaki
authors.affiliation: Department of Orthopedic Surgery, Sapporo Medical University School of Medicine, Sapporo, Hokkaido, Japan.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Nagoya
authors.affiliation: Department of Diagnostic Pathology, Sapporo Medical University School of Medicine, Sapporo, Hokkaido, Japan.
authors.forename: Tadashi
authors.initials: T
authors.lastname: Hasegawa
authors.affiliation: Department of Orthopedic Surgery, Saiseikai Otaru Hospital, Otaru, Hokkaido, Japan.
authors.forename: Takuro
authors.initials: T
authors.lastname: Wada
authors.affiliation: Department of Pathology, Sapporo Medical University School of Medicine, Sapporo, Hokkaido, Japan.
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Sato
authors.affiliation: Department of Orthopedic Surgery, Sapporo Medical University School of Medicine, Sapporo, Hokkaido, Japan.
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Yamashita
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015703:Antigens, CD / Q000096:biosynthesis*; D005260:Female; D005354:Fibrosarcoma / Q000378:metabolism* / Q000473:pathology / Q000601:surgery; D058851:GPI-Linked Proteins / Q000096:biosynthesis; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000096:biosynthesis*; D009364:Neoplasm Recurrence, Local / Q000378:metabolism*; D011379:Prognosis
chemical_list: D015703:Antigens, CD; C120523:CD109 protein, human; D058851:GPI-Linked Proteins; D009363:Neoplasm Proteins
keywords: CD109; myxofibrosarcoma; prognostic marker